Developer docs
API playgroundTry for free, no card

Search company profiles

AB Studio

Full company profile

uuid000c83a

Namestring
AB Studio
Legal namestring
Ab Studio Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

AB Studio (Ab Studio Inc., dba Antibody Studio) is a privately held biotechnology company founded in 2017 and headquartered in Hayward, California (San Francisco Bay Area). The company focuses on the rapid discovery, engineering, and optimization of complex therapeutic antibodies — bispecific, trispecific, and multi-specific formats — for biopharma and pharmaceutical clients. Its technology stack combines AI-assisted Computer Aided Antibody Design (CAAD) with traditional hybridoma, phage display, and B-cell technologies, layered over seven-plus proprietary platforms: FETA (Fc-enabled T-cell activation engaging T, macrophage, and NK cells), CATA (catalytic antibodies for protein aggregation diseases), GETA (VHH-directed AAV delivery for gene therapy), Brain Shuttle (nanobody BBB penetration for CNS), Imbalanced Bispecific, Serial Internalizing, Humanized VHH Discovery, and ETYY (heterodimer formation/manufacturability), plus Abprotac for targeted protein degradation. The team's work has produced multiple clinical-stage assets, including GB261 (CD20/CD3, Phase 2 B-NHL; Phase 1 autoimmune), GB263 (EGFR/c-Met/c-Met, Phase 1/2 NSCLC), and contributed to BMS's Tau program (Phase 2) and Novo Nordisk's ATTR program (Phase 3, coramitug), as well as ABS-VIR-001 (an anti-COVID-19 tri-specific).

The company operates a hybrid business model. The first stream is platform and asset licensing — AB Studio has licensed more than six bispecific antibody assets to biopharmas including Genor Biopharma/Candid Therapeutics (GB261/CND261), Eddingpharm (GB263), and China Resources Biopharma (ABS-VIR-001). The second stream is contract research and service revenue, with over 200 partner/service projects completed providing antibody discovery, engineering, humanization, 3D modeling, production, and biophysical/biological assay services to biotech and pharma clients. Distribution is direct B2B field sales, supported by participation in major industry conferences (JP Morgan Healthcare, AACR, PEGS, BIO), peer-reviewed publications, and a professional website. The headcount is 11-50 with approximately 70% PhD/MD scientists, led by founder and CEO Yue Liu, PhD, who is the named inventor on most clinical-stage programs. IP strategy is active, with US and Chinese patent grants on the Catabody and ETYY platforms in 2025.

Short descriptiontext

AB Studio is a Bay Area biotech founded in 2017 that develops complex therapeutic antibodies — bispecific, trispecific, and multi-specific — using AI-assisted CAAD design and proprietary platforms (FETA, CATA, Brain Shuttle, ETYY, GETA), licensing assets to biopharmas and delivering CRO discovery and engineering services to pharma clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic antibody development, bispecific antibody engineering, antibody discovery services, computer aided antibody design, antibody licensing platforms
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Antibody Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing of Bi/Tri-specific Antibody Assets
TypeLicensing Royalties
Description

AB Studio licenses its proprietary bi-specific and tri-specific antibody assets to biopharma companies. Multiple assets have been licensed including GB261 to Genor Biopharma/Candid Therapeutics and GB263 to Eddingpharm.

antibodystudio.com
2Partner/Service Projects (CRO Services)
TypeProfessional Services
Description

The company completes over 200 partner and service projects annually providing antibody discovery, engineering, humanization, and optimization services to pharmaceutical and biotech clients.

antibodystudio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AB Studio develops complex therapeutic antibodies by combining AI/Computer Aided Antibody Design (CAAD) with traditional hybridoma and phage display technologies. The company licenses proprietary bi/tri-specific antibody assets (such as GB261 and GB263) to biopharma partners and delivers contract research services spanning antibody discovery, engineering, humanization, 3D modeling, production, and biophysical/biological characterization.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AB Studio is a biotechnology company offering a portfolio of proprietary therapeutic antibody technology platforms combined with contract research and development services. The core platforms include FETA (Fc-enabled T cell activation), CATA (catalytic antibody for protein aggregation disorders), GETA (VHH-directed AAV delivery), Abprotac, Brain Shuttle (BBB penetration), Imbalanced Bispecific, Serial Internalizing, Humanized VHH Discovery, and ETYY platforms. These underlying technology platforms are complemented by CAAD (Computer Aided Antibody Design) computational tools and a comprehensive suite of services spanning antibody discovery, engineering, 3D modeling, production, and biological/biophysical characterization. The company operates a hybrid business model combining platform licensing with service partnerships.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-16
Description

Research collaboration to discover and develop novel T cell engagers (TCE) for autoimmune indications. This partnership builds on the existing licensing of GB261/CND261 (Fc-enabled CD20/CD3 bispecific antibody) which is in Phase I/II for B-NHL and Phase I for autoimmune diseases.

2China Resources Biopharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-16
Description

Partnered with China Resources Biopharma for ABS-VIR-001, the world's first anti-COVID19 tri-specific antibody candidate.

antibodystudio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-14
Description

Research collaboration partnership for antibody development.

4Genor Biopharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensed GB261 (Fc-enabled CD20/CD3 bispecific antibody invented at Ab Studio) with Phase 2 data in B-NHL. This asset was subsequently licensed to Candid Therapeutics.

antibodystudio.com
5Eddingpharm
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensed EGFR/c-Met/c-Met tri-specific antibody program (GB263, Phase I/II for NSCLC).

antibodystudio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing antibody-based therapeutics with proprietary bispecific and masking platforms. Comparable as a bispecific antibody platform company with partnered clinical assets.

TypeDirect peer
Description

Bispecific and multispecific antibody platform company with multiple clinical-stage assets. Directly comparable to AB Studio's focus on bispecific antibody engineering and licensing model with major pharma partners.

TypeEmerging player
Description

Developer of T cell engagers (COBRA platform) for solid tumors, acquired by Takeda in 2024. Comparable emerging player in the TCE space that overlaps with AB Studio's FETA platform technology.

TypeBroad incumbent
Description

Global biotech providing antibody discovery services, gene synthesis, and biologics manufacturing. Comparable as an antibody CRO service provider with overlapping customer base to AB Studio.

TypeBroad incumbent
Description

Global leader in biologics CRO/CDMO services with broad antibody discovery, engineering, and manufacturing capabilities. Comparable to AB Studio's CRO service business and bispecific antibody platforms, though at significantly larger scale.

TypeDirect peer
Description

Clinical-stage bispecific antibody developer with platforms spanning multiple indications. Comparable to AB Studio's bispecific antibody focus and clinical-stage partnership model.

TypeDirect peer
Description

Developer of T cell engager platforms (TriTAC) for oncology and infectious disease, acquired by Merck in 2024. Highly comparable to AB Studio's FETA T cell activation platform and TCE focus.

TypeDirect peer
Description

Multi-specific antibody engineering platform with proprietary technology for building tri-specific antibodies. Closely comparable to AB Studio's multispecific antibody focus and licensing approach.

TypeDirect peer
Description

Developer of the XmAb bispecific antibody engineering platform with multiple clinical assets and pharma partnerships. Closely comparable business model combining proprietary bispecific platform technology with licensing to biopharma.

TypeDirect peer
Description

AI-powered antibody discovery platform with partnered programs in the clinic. Highly comparable to AB Studio as both monetize proprietary antibody discovery/engineering platforms through licensing partnerships with biopharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AB Studio

Therapeutic Antibody Developmentantibodystudio.com

AB Studio is a Bay Area biotech founded in 2017 that develops complex therapeutic antibodies — bispecific, trispecific, and multi-specific — using AI-assisted CAAD design and proprietary platforms (FETA, CATA, Brain Shuttle, ETYY, GETA), licensing assets to biopharmas and delivering CRO discovery and engineering services to pharma clients.

What AB Studio does

AB Studio (Ab Studio Inc., dba Antibody Studio) is a privately held biotechnology company founded in 2017 and headquartered in Hayward, California (San Francisco Bay Area). The company focuses on the rapid discovery, engineering, and optimization of complex therapeutic antibodies — bispecific, trispecific, and multi-specific formats — for biopharma and pharmaceutical clients. Its technology stack combines AI-assisted Computer Aided Antibody Design (CAAD) with traditional hybridoma, phage display, and B-cell technologies, layered over seven-plus proprietary platforms: FETA (Fc-enabled T-cell activation engaging T, macrophage, and NK cells), CATA (catalytic antibodies for protein aggregation diseases), GETA (VHH-directed AAV delivery for gene therapy), Brain Shuttle (nanobody BBB penetration for CNS), Imbalanced Bispecific, Serial Internalizing, Humanized VHH Discovery, and ETYY (heterodimer formation/manufacturability), plus Abprotac for targeted protein degradation. The team's work has produced multiple clinical-stage assets, including GB261 (CD20/CD3, Phase 2 B-NHL; Phase 1 autoimmune), GB263 (EGFR/c-Met/c-Met, Phase 1/2 NSCLC), and contributed to BMS's Tau program (Phase 2) and Novo Nordisk's ATTR program (Phase 3, coramitug), as well as ABS-VIR-001 (an anti-COVID-19 tri-specific).

The company operates a hybrid business model. The first stream is platform and asset licensing — AB Studio has licensed more than six bispecific antibody assets to biopharmas including Genor Biopharma/Candid Therapeutics (GB261/CND261), Eddingpharm (GB263), and China Resources Biopharma (ABS-VIR-001). The second stream is contract research and service revenue, with over 200 partner/service projects completed providing antibody discovery, engineering, humanization, 3D modeling, production, and biophysical/biological assay services to biotech and pharma clients. Distribution is direct B2B field sales, supported by participation in major industry conferences (JP Morgan Healthcare, AACR, PEGS, BIO), peer-reviewed publications, and a professional website. The headcount is 11-50 with approximately 70% PhD/MD scientists, led by founder and CEO Yue Liu, PhD, who is the named inventor on most clinical-stage programs. IP strategy is active, with US and Chinese patent grants on the Catabody and ETYY platforms in 2025.

AB Studio firmographics

Firmographics
Name
AB Studio
Legal name
Ab Studio Inc.
Website
https://antibodystudio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
AB Studio is a Bay Area biotech founded in 2017 that develops complex therapeutic antibodies — bispecific, trispecific, and multi-specific — using AI-assisted CAAD design and proprietary platforms (FETA, CATA, Brain Shuttle, ETYY, GETA), licensing assets to biopharmas and delivering CRO discovery and engineering services to pharma clients.
Ownership category
akta.pro rank

AB Studio industry classification

Industry
Product category
Therapeutic Antibody Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Therapeutic antibody development
  • Bispecific antibody engineering
  • Antibody discovery services
  • Computer aided antibody design
  • Antibody licensing platforms

Where AB Studio is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AB Studio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing of Bi/Tri-specific Antibody Assets: AB Studio licenses its proprietary bi-specific and tri-specific antibody assets to biopharma companies. Multiple assets have been licensed including GB261 to Genor Biopharma/Candid Therapeutics and GB263 to Eddingpharm.
  2. Partner/Service Projects (CRO Services): The company completes over 200 partner and service projects annually providing antibody discovery, engineering, humanization, and optimization services to pharmaceutical and biotech clients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AB Studio product offering

Product offering

Core offering

AB Studio develops complex therapeutic antibodies by combining AI/Computer Aided Antibody Design (CAAD) with traditional hybridoma and phage display technologies. The company licenses proprietary bi/tri-specific antibody assets (such as GB261 and GB263) to biopharma partners and delivers contract research services spanning antibody discovery, engineering, humanization, 3D modeling, production, and biophysical/biological characterization.

Product overview

AB Studio is a biotechnology company offering a portfolio of proprietary therapeutic antibody technology platforms combined with contract research and development services. The core platforms include FETA (Fc-enabled T cell activation), CATA (catalytic antibody for protein aggregation disorders), GETA (VHH-directed AAV delivery), Abprotac, Brain Shuttle (BBB penetration), Imbalanced Bispecific, Serial Internalizing, Humanized VHH Discovery, and ETYY platforms. These underlying technology platforms are complemented by CAAD (Computer Aided Antibody Design) computational tools and a comprehensive suite of services spanning antibody discovery, engineering, 3D modeling, production, and biological/biophysical characterization. The company operates a hybrid business model combining platform licensing with service partnerships.

Differentiator

Problem solved

Functional benefit

Companies that use AB Studio

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

AB Studio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature10 records

AB Studio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Candid TherapeuticscoreStrategic or Co-development Partner · 16 December 2024Research collaboration to discover and develop novel T cell engagers (TCE) for autoimmune indications. This partnership builds on the existing licensing of GB261/CND261 (Fc-enabled CD20/CD3 bispecific antibody) which is in Phase I/II for B-NHL and Phase I for autoimmune diseases.
  • China Resources BiopharmacoreStrategic or Co-development Partner · 16 March 2022Partnered with China Resources Biopharma for ABS-VIR-001, the world's first anti-COVID19 tri-specific antibody candidate.
  • IntoCellminorStrategic or Co-development Partner · 14 October 2021Research collaboration partnership for antibody development.
  • Genor BiopharmacoreStrategic or Co-development PartnerLicensed GB261 (Fc-enabled CD20/CD3 bispecific antibody invented at Ab Studio) with Phase 2 data in B-NHL. This asset was subsequently licensed to Candid Therapeutics.
  • EddingpharmcoreStrategic or Co-development PartnerLicensed EGFR/c-Met/c-Met tri-specific antibody program (GB263, Phase I/II for NSCLC).

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

AB Studio competitors and assessment

Company assessment

Direct peers

  • Adagene: Clinical-stage biotechnology company developing antibody-based therapeutics with proprietary bispecific and masking platforms. Comparable as a bispecific antibody platform company with partnered clinical assets.
  • Zymeworks: Bispecific and multispecific antibody platform company with multiple clinical-stage assets. Directly comparable to AB Studio's focus on bispecific antibody engineering and licensing model with major pharma partners.
  • Compass Therapeutics: Clinical-stage bispecific antibody developer with platforms spanning multiple indications. Comparable to AB Studio's bispecific antibody focus and clinical-stage partnership model.
  • Harpoon Therapeutics: Developer of T cell engager platforms (TriTAC) for oncology and infectious disease, acquired by Merck in 2024. Highly comparable to AB Studio's FETA T cell activation platform and TCE focus.
  • Numab Therapeutics: Multi-specific antibody engineering platform with proprietary technology for building tri-specific antibodies. Closely comparable to AB Studio's multispecific antibody focus and licensing approach.
  • Xencor: Developer of the XmAb bispecific antibody engineering platform with multiple clinical assets and pharma partnerships. Closely comparable business model combining proprietary bispecific platform technology with licensing to biopharma.
  • AbCellera Biologics: AI-powered antibody discovery platform with partnered programs in the clinic. Highly comparable to AB Studio as both monetize proprietary antibody discovery/engineering platforms through licensing partnerships with biopharma.

Emerging players

  • Maverick Therapeutics: Developer of T cell engagers (COBRA platform) for solid tumors, acquired by Takeda in 2024. Comparable emerging player in the TCE space that overlaps with AB Studio's FETA platform technology.

Broad incumbents

  • GenScript: Global biotech providing antibody discovery services, gene synthesis, and biologics manufacturing. Comparable as an antibody CRO service provider with overlapping customer base to AB Studio.
  • WuXi Biologics: Global leader in biologics CRO/CDMO services with broad antibody discovery, engineering, and manufacturing capabilities. Comparable to AB Studio's CRO service business and bispecific antibody platforms, though at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

AB Studio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AB Studio leadership team

Management profile

Number of profiles

Profiles1 record

AB Studio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AB Studio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AB Studio

What does AB Studio do?

AB Studio develops complex therapeutic antibodies by combining AI/Computer Aided Antibody Design (CAAD) with traditional hybridoma and phage display technologies. The company licenses proprietary bi/tri-specific antibody assets (such as GB261 and GB263) to biopharma partners and delivers contract research services spanning antibody discovery, engineering, humanization, 3D modeling, production, and biophysical/biological characterization.

Is AB Studio a public or private company?

AB Studio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AB Studio founded?

AB Studio was founded in 2017. It employs 11 to 50 people.

Where is AB Studio based?

AB Studio is headquartered in Hayward, United States, in the North America region.

How does AB Studio make money?

Two revenue lines are on record. Licensing of Bi/Tri-specific Antibody Assets are the primary driver. The others are partner/Service Projects (CRO Services).

Who are AB Studio's main competitors?

Direct peers on record are Adagene, Zymeworks, Compass Therapeutics, Harpoon Therapeutics, Numab Therapeutics, Xencor and AbCellera Biologics. Maverick Therapeutics is listed as an emerging player. Broad incumbents are GenScript and WuXi Biologics.

Does AB Studio have an API?

No public API is recorded for AB Studio.

What industry is AB Studio in?

AB Studio's product category is Therapeutic Antibody Development. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldCATA-001 yields promising results for light chain multiple myelomaAb Studio's CATA-001 is a bispecific antibody targeting CD38 and aggregated light chains to deplete plasma cells and clear pathogenic free light chain aggregates. It is designed for light chain multiple myeloma and AL amyloidosis, with promising results reported.PR NewswirePharmaVentures advises IntoCell on its Research Collaboration with Ab StudioPharmaVentures advised IntoCell on its research collaboration with Ab Studio to develop antibody drug conjugates using IntoCell's OHPAS linker and PMT payloads. The collaboration combines IntoCell's technology with Ab Studio's antibody discovery approach. IntoCell plans IND-enabling studies for its lead candidate ITC-6146RO in 2022.PR NewswireIntoCell and Ab Studio to Start Research CollaborationIntoCell and Ab Studio signed a research collaboration to develop antibody drug conjugates (ADCs) combining IntoCell's OHPAS linker and payloads with Ab Studio's internalizing antibodies. The ADCs will be evaluated for anti-tumor activity and considered for IND-enabling studies. IntoCell plans IND-enabling studies for its lead candidate ITC-6146RO in 2022.NatureInnovative antibodies with better safety, efficacy and manufacturability balanceAb Studio combines traditional antibody discovery with computer-aided design to optimize therapeutic antibodies for safety, efficacy, and manufacturability. Its GB261 bispecific antibody, combining rituximab and an anti-CD3 arm, showed enhanced tumor killing and reduced cytokine release risk in preclinical studies. The drug is licensed to JHBP and will enter phase 1 trials soon.